Show simple item record

Files in this item


Item metadata

dc.contributor.authorMorales, Daniel R
dc.contributor.authorDonnan, Peter T
dc.contributor.authorDaly, Fergus
dc.contributor.authorStaa, Tjeerd Van
dc.contributor.authorSullivan, Frank M
dc.identifier.citationMorales , D R , Donnan , P T , Daly , F , Staa , T V & Sullivan , F M 2013 , ' Impact of clinical trial findings on Bell's palsy management in general practice in the UK 2001-2012 : Interrupted time series regression analysis ' , BMJ Open , vol. 3 , no. 7 , e003121 . ,
dc.identifier.otherPURE: 256233334
dc.identifier.otherPURE UUID: bfa50a05-2de7-4003-8c39-1554955b0fc8
dc.identifier.otherScopus: 84880593632
dc.identifier.otherPubMed: 23864211
dc.identifier.otherPubMedCentral: PMC3717449
dc.identifier.otherORCID: /0000-0002-6623-4964/work/49580224
dc.description.abstractOBJECTIVES: To measure the incidence of Bell's palsy and determine the impact of clinical trial findings on Bell's palsy management in the UK. DESIGN: Interrupted time series regression analysis and incidence measures. SETTING: General practices in the UK contributing to the Clinical Practice Research Datalink (CPRD). PARTICIPANTS: Patients ≥16 years with a diagnosis of Bell's palsy between 2001 and 2012. INTERVENTIONS: (1) Publication of the 2004 Cochrane reviews of clinical trials on corticosteroids and antivirals for Bell's palsy, which made no clear recommendation on their use and (2) publication of the 2007 Scottish Bell's Palsy Study (SBPS), which made a clear recommendation that treatment with prednisolone alone improves chances for complete recovery. MAIN OUTCOME MEASURES: Incidence of Bell's palsy per 100 000 person-years. Changes in the management of Bell's palsy with either prednisolone therapy, antiviral therapy, combination therapy (prednisolone with antiviral therapy) or untreated cases. RESULTS: During the 12-year period, 14 460 cases of Bell's palsy were identified with an overall incidence of 37.7/100 000 person-years. The 2004 Cochrane reviews were associated with immediate falls in prednisolone therapy (-6.3% (-11.0 to -1.6)), rising trends in combination therapy (1.1% per quarter (0.5 to 1.7)) and falling trends for untreated cases (-0.8% per quarter (-1.4 to -0.3)). SBPS was associated with immediate increases in prednisolone therapy (5.1% (0.9 to 9.3)) and rising trends in prednisolone therapy (0.7% per quarter (0.4 to 1.2)); falling trends in combination therapy (-1.7% per quarter (-2.2 to -1.3)); and rising trends for untreated cases (1.2% per quarter (0.8 to 1.6)). Despite improvements, 44% still remain untreated. CONCLUSIONS: SBPS was clearly associated with change in management, but a significant proportion of patients failed to receive effective treatment, which cannot be fully explained. Clarity and uncertainty in clinical trial recommendations may change clinical practice. However, better ways are needed to understand and circumvent barriers in implementing clinical trial findings.
dc.relation.ispartofBMJ Openen
dc.rightsPublished by the BMJ Publishing Group Limited. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
dc.subjectRA Public aspects of medicineen
dc.titleImpact of clinical trial findings on Bell's palsy management in general practice in the UK 2001-2012 : Interrupted time series regression analysisen
dc.typeJournal articleen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Sir James Mackenzie Institute for Early Diagnosisen
dc.contributor.institutionUniversity of St Andrews. Population and Behavioural Science Divisionen
dc.description.statusPeer revieweden

This item appears in the following Collection(s)

Show simple item record